Christine M Veenstra1, Scott E Regenbogen, Sarah T Hawley, Jennifer J Griggs, Mousumi Banerjee, Ikuko Kato, Kevin C Ward, Arden M Morris. 1. *Department of Internal Medicine, Division of Hematology/Oncology †Department of Surgery, Division of Colorectal Surgery, Center for Healthcare Outcomes and Policy ‡Division of General Medicine, Cancer Surveillance and Outcomes Research Team §Department of Internal Medicine, Division of Hematology/Oncology, Center for Healthcare Outcomes and Policy, Cancer Surveillance and Outcomes Research Team ∥Department of Biostatistics, Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor ¶Department of Pathology, Wayne State University, Detroit, MI #Department of Epidemiology, Georgia Center for Cancer Statistics, Rollins School of Public Health, Emory University, Atlanta, GA **Department of Surgery, Division of Colorectal Surgery, Center for Healthcare Outcomes and Policy, Cancer Surveillance and Outcomes Research Team, University of Michigan, Ann Arbor, MI.
Abstract
BACKGROUND: Despite improved survival with chemotherapy for stage III colorectal cancer (CRC), patients may suffer substantial economic hardship during treatment. Methods for quantifying financial burden in CRC patients are lacking. OBJECTIVE: To derive and validate a novel patient-reported measure of personal financial burden during CRC treatment. DATA COLLECTION: Within a population-based survey of patients in the Detroit and Georgia Surveillance, Epidemiology and End Results regions diagnosed with stage III CRC between 2011 and 2013, we asked 7 binary questions assessing effects of disease and treatment on personal finances. DATA ANALYSIS: We used factor analysis to compute a composite measure of financial burden. We used χ tests to evaluate relationships between individual components of financial burden and chemotherapy use with χ analyses. We used Mantel-Haenszel χ trend tests to examine relationships between the composite financial burden metric and chemotherapy use. RESULTS: Among 956 patient surveys (66% response rate), factor analysis of 7 burden items yielded a single-factor solution. Factor loadings of 6 items were >0.4; these were included in the composite score. Internal consistency was high (Cronbach α=0.79). The mean financial burden score among all respondents was 1.72 (range, 0-6). The 812 (85%) who reported chemotherapy use had significantly higher financial burden scores than those who did not (mean burden score 1.88 vs. 0.88, P<0.001). CONCLUSIONS: Financial burden is high among CRC patients, particularly those who use adjuvant chemotherapy. We encourage use of our instrument to validate our measure in the identification of patients in need of additional financial support during treatment.
BACKGROUND: Despite improved survival with chemotherapy for stage III colorectal cancer (CRC), patients may suffer substantial economic hardship during treatment. Methods for quantifying financial burden in CRC patients are lacking. OBJECTIVE: To derive and validate a novel patient-reported measure of personal financial burden during CRC treatment. DATA COLLECTION: Within a population-based survey of patients in the Detroit and Georgia Surveillance, Epidemiology and End Results regions diagnosed with stage III CRC between 2011 and 2013, we asked 7 binary questions assessing effects of disease and treatment on personal finances. DATA ANALYSIS: We used factor analysis to compute a composite measure of financial burden. We used χ tests to evaluate relationships between individual components of financial burden and chemotherapy use with χ analyses. We used Mantel-Haenszel χ trend tests to examine relationships between the composite financial burden metric and chemotherapy use. RESULTS: Among 956 patient surveys (66% response rate), factor analysis of 7 burden items yielded a single-factor solution. Factor loadings of 6 items were >0.4; these were included in the composite score. Internal consistency was high (Cronbach α=0.79). The mean financial burden score among all respondents was 1.72 (range, 0-6). The 812 (85%) who reported chemotherapy use had significantly higher financial burden scores than those who did not (mean burden score 1.88 vs. 0.88, P<0.001). CONCLUSIONS: Financial burden is high among CRC patients, particularly those who use adjuvant chemotherapy. We encourage use of our instrument to validate our measure in the identification of patients in need of additional financial support during treatment.
Authors: Kenneth M Langa; A Mark Fendrick; Michael E Chernew; Mohammed U Kabeto; Kerry L Paisley; James A Hayman Journal: Value Health Date: 2004 Mar-Apr Impact factor: 5.725
Authors: Ahsan M Arozullah; Elizabeth A Calhoun; Michael Wolf; Denise K Finley; Karen A Fitzner; Elizabeth A Heckinger; Nicolle S Gorby; Glen T Schumock; Charles L Bennett Journal: J Support Oncol Date: 2004 May-Jun
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Scott E Regenbogen; Christine M Veenstra; Sarah T Hawley; Mousumi Banerjee; Kevin C Ward; Ikuko Kato; Arden M Morris Journal: Cancer Date: 2014-05-29 Impact factor: 6.860
Authors: Matthew P Banegas; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Stephanie Nutt; Loyce Pace; Alexandra Varga; Lisa Waiwaiole; Jennifer Schneider; K Robin Yabroff Journal: J Cancer Surviv Date: 2017-08-29 Impact factor: 4.442
Authors: Matthew P Banegas; Gery P Guy; Janet S de Moor; Donatus U Ekwueme; Katherine S Virgo; Erin E Kent; Stephanie Nutt; Zhiyuan Zheng; Ruth Rechis; K Robin Yabroff Journal: Health Aff (Millwood) Date: 2016-01 Impact factor: 6.301
Authors: Arielle E Kanters; Arden M Morris; Paul H Abrahamse; Lona Mody; Pasithorn A Suwanabol Journal: Dis Colon Rectum Date: 2018-07 Impact factor: 4.585
Authors: Grace L Smith; Maria A Lopez-Olivo; Pragati G Advani; Matthew S Ning; Yimin Geng; Sharon H Giordano; Robert J Volk Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Cheryl K Altice; Matthew P Banegas; Reginald D Tucker-Seeley; K Robin Yabroff Journal: J Natl Cancer Inst Date: 2016-10-20 Impact factor: 13.506
Authors: Gelareh Sadigh; Jeffrey Switchenko; Kathryn E Weaver; Deema Elchoufi; Jane Meisel; Mehmet Asim Bilen; David Lawson; David Cella; Bassel El-Rayes; Ruth Carlos Journal: Support Care Cancer Date: 2021-07-13 Impact factor: 3.603
Authors: Debbie W Chen; David Reyes-Gastelum; Christine M Veenstra; Ann S Hamilton; Mousumi Banerjee; Megan R Haymart Journal: Thyroid Date: 2020-09-22 Impact factor: 6.568